NeOnc's $50mln cornerstone investment finalized, MENA expansion underway.

NeOnc Technologies Holdings, a biotechnology company, has announced the official incorporation of NuroMENA Holdings Ltd by the Abu Dhabi Global Market. This milestone completes the $50 million cornerstone investment led by Quazar Investment, supporting the launch of NeOnc's CNS platform across the MENA region and accelerating its therapeutic pipeline development.

NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biotechnology company focused on therapies for central nervous system (CNS) cancers, has announced the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). This milestone completes the $50 million cornerstone investment led by Quazar Investment, supporting the launch of NeOnc's CNS platform across the MENA region and accelerating its therapeutic pipeline development.

The strategic partnership will enable NeOnc to establish a robust presence in the Middle East and North Africa (MENA) region, where advanced biotechnology infrastructure is currently lacking but offers significant market potential. The investment will also accelerate the development of NeOnc's clinical programs, NEO212 and NEO100, which are currently in Phase 2 trials.

Quazar Investment, a leading strategic investment firm headquartered in Abu Dhabi, will take majority control of NuroMENA Holdings following the investment closing. The arrangement will include joint governance oversight between NeOnc and Quazar to ensure strategic alignment and accelerate breakthrough CNS therapies across the region.

"This is a defining moment for NeOnc," said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. "With the finalization of NuroMENA’s incorporation and the support of Quazar Investment, we are now fully equipped to continue our goals toward delivering life-saving therapies to a region in urgent need of innovation."

Waleed K. Al Ali, Chairman and CEO of Quazar Investment, added, "We are proud to partner with NeOnc to bring cutting-edge biotechnology to the UAE and beyond. With NuroMENA now officially formed under ADGM, we are positioned to assist NeOnc with efforts to transform the landscape of brain cancer and CNS treatment across the region."

The official incorporation of NuroMENA Holdings Ltd. under ADGM on August 6, 2025, marks a critical milestone for NeOnc, fulfilling all contingencies for the $50 million strategic investment. This deal represents a significant capital infusion for a clinical-stage biotech company with multiple Phase 2 programs targeting the challenging CNS cancer space.

References:
[1] https://www.globenewswire.com/news-release/2025/08/11/3130952/0/en/NeOnc-Technologies-Finalizes-All-Contingencies-for-50-Million-Strategic-Partnership-with-Quazar-Investment-as-NuroMENA-Holdings-Receives-ADGM-Incorporation.html
[2] https://www.marketscreener.com/news/neonc-technologies-finalizes-all-contingencies-for-50-million-strategic-partnership-with-quazar-inv-ce7c5ed2de81f424
[3] https://www.stocktitan.net/news/NTHI/ne-onc-technologies-finalizes-all-contingencies-for-50-million-xdu5lyturomj.html